Drugs / Withania somnifera
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05031351 | Oct 2021 → Jul 2022 | amyotrophic lateral sclerosis | Sunnybrook Health Sciences Centre | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07578857 | May → Oct 2023 | hyperlipidemia | Riphah International University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Withania somnifera | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05031351 ↗ |
| Route | Oral | “544mg oral twice a day” NCT05031351 ↗ |